---
title: "Understanding the Market | TRANSTHERA-B rises over 15% again, total market value surpasses HKD 40 billion, and the Phase II clinical trial for Engeletinib is approved to proceed"
description: "TRANSTHERA-B rose over 15% again, with a total market value briefly surpassing HKD 40 billion. As of the time of publication, it rose 11.11%, trading at HKD 100, with a transaction volume of HKD 148 m"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/256837391.md"
published_at: "2025-09-11T02:53:04.000Z"
---

# Understanding the Market | TRANSTHERA-B rises over 15% again, total market value surpasses HKD 40 billion, and the Phase II clinical trial for Engeletinib is approved to proceed

> TRANSTHERA-B rose over 15% again, with a total market value briefly surpassing HKD 40 billion. As of the time of publication, it rose 11.11%, trading at HKD 100, with a transaction volume of HKD 148 million. In terms of news, TRANSTHERA announced that its core product, TT-00420, in combination with Fulvestrant, has received clinical implied approval from the National Medical Products Administration of China for a Phase II clinical trial treating hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative or low-expressing (HER2-) recurrent or metastatic breast cancer that has failed previous treatments. The clinical treatment strategy of combining TT-00420 with Fulvestrant may bring new breakthroughs in the treatment of breast cancer patients. In addition, the Shanghai Stock Exchange and Shenzhen Stock Exchange recently announced that TRANSTHERA has been added to the Hong Kong Stock Connect eligible list, effective from September 8. Guoyuan International stated that the company is a leader in R&D within its niche industry, and TT-00420 is the world's first and only FGFR inhibitor to enter the registration clinical stage for the treatment of recurrent or refractory cholangiocarcinoma patients. It is also the world's first investigational drug that may simultaneously inhibit the FGFR/JAK pathway and has clinical efficacy evidence targeting metastatic castration-resistant prostate cancer

According to Zhitong Finance APP, TRANSTHERA-B (02617) has risen over 15% again, with a total market value briefly surpassing HKD 40 billion. As of the time of publication, it has increased by 11.11%, trading at HKD 100, with a transaction volume of HKD 148 million.

In terms of news, TRANSTHERA announced that its core product, TT-00420, in combination with Fulvestrant, has received clinical implied approval from the National Medical Products Administration of China for a Phase II clinical trial treating hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative or low-expressing (HER2-) recurrent or metastatic breast cancer that has failed previous treatments. The clinical treatment strategy of TT-00420 combined with Fulvestrant may bring new breakthroughs in the treatment of breast cancer patients.

Additionally, the Shanghai Stock Exchange and Shenzhen Stock Exchange recently announced that TRANSTHERA has been added to the Hong Kong Stock Connect eligible list, effective from September 8. Guoyuan International stated that the company is a leader in research and development in its niche industry, and TT-00420 is the world's first and only FGFR inhibitor to enter the registration clinical stage for the treatment of recurrent or refractory cholangiocarcinoma patients. It is also the world's first research drug that may simultaneously inhibit the FGFR/JAK pathway and has clinical efficacy evidence targeting metastatic castration-resistant prostate cancer

### Related Stocks

- [02617.HK - TRANSTHERA-B](https://longbridge.com/en/quote/02617.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 港股异动：基石投资者解禁引发担忧，药捷安康-B 股价暴跌 16.36% | 药捷安康-B 跌 16.36%；信达生物涨 0.92%，成交额达到 2.51 亿港币；三生制药涨 1.68%，成交额达到 1.83 亿港币；荣昌生物涨 0.92%，成交额达到 1.37 亿港币；百济神州涨 0.43%，市值达到 2889 亿 | [Link](https://longbridge.com/en/news/270561769.md) |
| 港股异动：药捷安康-B 涨 16.21%，资金流向活跃，板块趋势引发市场关注？ | 药捷安康-B 涨 16.21%；三生制药跌 1.44%，成交额达到 1.3 亿港币；信达生物跌 1.01%，成交额达到 1.17 亿港币；康方生物跌 1.52%，成交额达到 70.04 百万港币；百济神州跌 1.14%，市值达到 2799  | [Link](https://longbridge.com/en/news/271050704.md) |
| 06:16 ETSpace Prize Foundation 启动教育公平计划，惠及数百名布朗斯维尔学生及家庭 | Space Prize Foundation 今日宣布启动一项全新教育公平计划，旨在为德克萨斯州布朗斯维尔地区教育资源匮乏的学生和家庭，拓展参与太空与 STEM 实践学习的机会。该项目将为 500 余名二年级学生及 42 个家庭提供沉浸式博 | [Link](https://longbridge.com/en/news/276436056.md) |
| 翰森制药的关键肺癌药物奥莫替尼获得欧盟批准 | 翰森制药获得欧盟对关键肺癌药物阿莫雷替尼的批准 | [Link](https://longbridge.com/en/news/276393466.md) |
| 当 “飞机发动机” 成为 “数据中心供电” 标的 | 随着 AI 数据中心对电力需求的指数级增长，传统电网扩容的滞后已成为行业公敌。这一背景下，FTAI Aviation、ProEnergy 等公司正加速将航空动力资产 “降维” 引入电力市场。 | [Link](https://longbridge.com/en/news/276216835.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
